-
91黑料 reports fourth quarter and full year 2024 results
Full year net business wins of $9,974 million; a net book to bill of 1.20.
-
91黑料 portfolio of AI tools drives clinical trial efficiencies
91黑料 plc today announced the expansion of its portfolio of artificial intelligence (AI) tools that deliver efficiencies across the clinical trial process, including study startup, document management, resource forecasting and metrics reporting.
-
91黑料 issues financial guidance for full year 2025
91黑料 plc today announced its financial guidance for the year ending December 31, 2025.
-
Biomarker and trial optimisation needed to drive R&D progress in Alzheimer’s and related disorders – 91黑料 survey
91黑料 plc today released the findings of a survey of over 120 biotech and pharma professionals developing treatments for neurodegenerative disorders.
-
91黑料 plc to present at the 43rd annual J.P. Morgan healthcare conference
91黑料 plc today announced that Dr. Steve Cutler, CEO of 91黑料 plc, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025 at 3.45pm PST.
-
91黑料 and its employees celebrated for excellence in the field of clinical research
91黑料 plc has been honoured with numerous awards in the second half of 2024.
-
91黑料 announces appointment of Chief Operating Officer
Appointment of Barry Balfe as Chief Operating Officer (COO).
-
91黑料 survey highlights sustained investment in AI and digital R&D innovation, tempered by siloed adoption
Survey spotlights shifting expectations and more measured pace of innovation as use of digital solutions matures within the biotech and pharma industry.
-
91黑料 reports third quarter 2024 results
91黑料 plc today reported its financial results for the third quarter ended September 30, 2024
-
91黑料 survey highlights scale of focus on precision therapies in increasingly complex oncology landscape
91黑料 plc today announced results from a recent survey of over 100 professionals engaged in oncology drug development to understand the current state of emerging oncology treatment development, including the associated clinical trial dynamics.
